SureTrader
Home > Boards > US Listed > Biotechs > Intellipharmaceutics International Inc. (IPCI)

Fred- Those prescription numbers you posted also include

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
tilator Member Profile
 
Followed By 0
Posts 266
Boards Moderated 0
Alias Born 09/14/17
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/16/2018 6:32:05 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2018 11:13:52 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/14/2018 6:54:36 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/9/2018 8:08:58 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 1/24/2018 8:04:28 AM
Intellipharmaceutics Provides Operational Update GlobeNewswire Inc. - 1/24/2018 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 12/5/2017 8:05:20 AM
Intellipharmaceutics Announces Receipt of Nasdaq Notice GlobeNewswire Inc. - 12/5/2017 8:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/4/2017 5:21:01 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/30/2017 10:51:14 AM
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical GlobeNewswire Inc. - 11/30/2017 10:45:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/20/2017 5:20:34 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 10/18/2017 3:20:22 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/16/2017 6:03:43 AM
Intellipharmaceutics Announces Closing of US$4 Million Financing GlobeNewswire Inc. - 10/13/2017 5:45:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/13/2017 6:04:15 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/12/2017 4:07:48 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/11/2017 8:07:45 AM
Intellipharmaceutics Announces US$4 Million Registered Direct Offering GlobeNewswire Inc. - 10/11/2017 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/10/2017 5:25:56 PM
Intellipharmaceutics Announces Third Quarter 2017 Results GlobeNewswire Inc. - 10/10/2017 5:20:59 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/25/2017 7:12:00 AM
Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA GlobeNewswire Inc. - 9/25/2017 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/20/2017 5:18:47 PM
Intellipharmaceutics Announces Receipt of Nasdaq Notice GlobeNewswire Inc. - 9/20/2017 5:10:00 PM
tilator   Friday, 11/10/17 03:29:45 PM
Re: wimuskyfisherman post# 31192
Post # of 32844 
Quote:
Fred- Those prescription numbers you posted also include the standard Seroquel prescription as well as the XR. The standard prescriptions still far exceed the XR ones.



I suppose it has only XR:

"According to Symphony Health Solutions, sales of Seroquel XR® were approximately US$1.1 billion for the 12 months ending January 2017 (TRx MBS Dollars)."

http://www.intellipharmaceutics.com/product-detail.cfm?productID=118884

300k weekly prescriptions would make some US$1.5 billion sales if one prescription made US$100 sales.

I think there is really enough room for MNK sales, but do they take it seriously?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist